Global
Cancer Biomarkers Market, By Tumor (Breast, Lung, Prostate), By Type
(Protein Biomarker, Genetic Biomarkers), By Profiling Technology (Proteomics,
Genomics, Imaging, Immunoassay), By Application (Diagnostic, Drug Discovery,
Prognostic), By Geography (North America, Europe, Asia-Pacific, South America,
Rest of the World) – Industry Trends and Forecast to 2024
Request for Sample Report @ http://databridgemarketresearch.com/request-a-sample/?chalet=global-cancer-biomarkers-market
The
Global Cancer Biomarkers Market has accounted to USD 10.9 billion in 2016,
growing at a CAGR of 12.2% from 2017 to 2024, and is expected to reach USD 27.4
billion by 2024.
Cancer
biomarkers are the molecules secreted by a tumor or a specific response of the
human body indicating the presence of cancer. The biomarkers enable cancer
detection at an early stage and facilitate high-speed noninvasive diagnosis
using various genomics and proteomics tools. Cancer biomarkers are used for
various applications such as cancer diagnostics, drug discovery and
development, prognostics, personalized medicine, and surrogate endpoints. Over
the years, cancer biomarkers have become an integral part of research in
pharmaceutical and clinical trial companies, as they help to reduce the time
and cost of the drug discovery and development process.
In
this report, the cancer biomarkers market is segmented on the basis of type,
cancer type, profiling technology, application, and geography.
Based
on type, the cancer biomarkers market is broadly split into three segments,
namely, protein biomarkers, genetic biomarkers, and other biomarkers (includes
viral, cell, and carbohydrate biomarkers). In 2015, the protein biomarkers
segment accounted for the largest share of the global cancer biomarkers market.
The large share of this segment is mainly attributed to the tremendous
potential of protein biomarkers in cancer detection, diagnostics, prognostics,
and clinical & therapeutic applications; and low cost of the protein
biomarker tests as compared to genetic biomarker tests. The increasing focus of
pharmaceutical companies towards the discovery of protein biomarkers is further
expected to fuel the growth of this market in the coming years.
Based
on cancer type, the cancer
biomarkers market is categorized into breast cancer, lung cancer,
colorectal cancer, prostate cancer, cervical cancer, and other cancers
(includes melanoma, leukemia, gastric, kidney, liver, and pancreatic cancers).
In 2015, the breast cancer segment accounted for the largest share of the
global cancer biomarkers market. The largest share of this segment is mainly
attributed to the high prevalence of breast cancer over the last few years,
increased awareness about breast cancer diagnosis, and increasing research
focus on breast cancer. However, the lung cancer segment is expected to grow at
the highest CAGR during the forecast period. The high growth rate of this
segment can be attributed to the rising prevalence of lung cancer and
increasing research focus on lung cancer biomarkers.
The
cancer biomarkers market, by profiling technology, is segmented into omics
technologies, imaging technologies, immunoassays, cytogenetics, and
bioinformatics. The omics technologies segment accounted for the largest share
of the global cancer biomarkers market in 2015. The largest share of this
segment is mainly attributed to the increased adoption of advanced high
throughput technologies in biomarker discovery and development and increasing
use of omics-based tests for cancer diagnosis and drug development process.
Omics technologies also represent the fastest-growing cancer biomarkers
segment. The high growth rate of this segment can be attributed to the
increasing adoption of advanced omics technologies for cancer detection and
drug discovery & development applications, specifically in developing
countries. Advances in high-throughput omics technologies are also contributing
to the growth of this market, by increasing the space of prospective biomarkers
in cancer research.
On
the other hand, the share of imaging technologies is expected decrease in the
coming years due to increasing demand for other advanced technologies such as
genomics and proteomics which detects cancer in early stages and provides
information about tumors at molecular level compared imaging technologies.
Browse Full Report @ http://databridgemarketresearch.com/reports/pharmaceutical/global-cancer-biomarkers-market/
Based
on geography the global cancer biomarkers market is segmented into 5
geographical regions, North America, Europe, Asia-Pacific, South America and
rest of the world. The geographical regions are further segmented into 24 major
countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium,
Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia,
South Africa and many others.
Some of the major Companies operating
in this market are:
·
Abbott Laboratories
·
DiagnoCure Inc.
·
Affymetrix, Inc.
·
Illumina, Inc.
·
Qiagen N.V.
·
Roche Diagnostics Ltd.
·
Agilent Technologies Inc.
·
Quest Diagnostics Inc.
·
Merck & Co. Inc.
·
Hologic, Inc.
·
Becton Dickinson
Inquiry
before Buying @ http://databridgemarketresearch.com/inquire-before-buying/?chalet=global-cancer-biomarkers-market
Related
Report
Global
Radiopharmaceuticals Market – Industry Trends and Forecast to 2024
Global
Radiopharmaceuticals Market, By Type (Diagnostic, Therapeutic), Procedural
Volumes (Diagnostic Procedures, Therapeutic Procedures), Application, Sources
(Nuclear Reactors, Cyclotrons), End User, Geography (North America, Europe,
APAC, South America, MEA)– Industry Trends andForecast To 2024
Report Access: http://databridgemarketresearch.com/reports/pharmaceutical/global-radiopharmaceuticals-market-trends-forecast-2024/
About Data Bridge Market
Research:
Data Bridge
Market Research set forth itself as an unconventional and neoteric
Market research and consulting firm with unparalleled level of resilience and
integrated approaches. We are determined to unearth the best market
opportunities and foster efficient information for your business to thrive in
the market. Data Bridge endeavors to provide appropriate solutions to the
complex business challenges and initiates an effortless decision-making
process.
Contact:
Ankit
Singh
Data
Bridge Market Research
Tel:
+1-888-387-2818